Andover Eye Associates
Andover, Massachusetts, 01810, United States
NCT Number: NCT03162783
The objective of this study is to evaluate the safety, tolerability, and pharmacodynamic activity of ADX-102 Ophthalmic Solutions and ADX-102 Ophthalmic Lipid Solution in subjects with dry eye syndrome.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 2
Andover, Massachusetts, 01810, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
ADX-102 Ophthalmic Solution (0.5%) administered for approximately 4 weeks.
ADX-102 Ophthalmic Solution (0.1%) administered for approximately 4 weeks.
ADX-102 Ophthalmic Lipid Solution administered for approximately 4 weeks.
Time frame: Efficacy assessment period (Day 1 through Day 29), Day 29 reported.
Change from baseline of ADX-102 on ocular discomfort in subjects with dry eye disease using the Ora Calibra® Ocular Discomfort Scale (0 = least, 4 = most), where a higher score is indicative of a worse outcome. The intervention was administered bilaterally.
Aldeyra Therapeutics, Inc.
Industry
A Single-Center, Phase 2a, Randomized, Double Masked, Clinical Study to Assess the Safety, Tolerability, and Pharmacodynamic Activity of ADX-102 Ophthalmic Solution in Subjects With Dry Eye Syndrome
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05481450
Dry Eye, Dry Eye Syndromes
Lutz, Florida, United States
View Trial DetailsNCT06483750
Cataract Senile, Dry Eye Disease
Washington D.C., District of Columbia, United States
View Trial DetailsNCT07588074
Conjunctival Diseases, Conjunctivitis
Baton Rouge, Louisiana, United States
View Trial DetailsNCT04730336
Dry Eye, Dry Eye Syndromes
Solihull, United Kingdom
View Trial Details